Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
17.03
0.00 (0.00%)
Aug 26, 2026, 4:00 PM EDT - Market closed
Company Description
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.
It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA).
It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution.
Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Theravance Biopharma, Inc.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 90 |
| CEO | Rick Winningham |
Contact Details
Address: 901 Gateway Boulevard South San Francisco, California 94080 United States | |
| Phone | 650 808 6000 |
| Website | theravance.com |
Stock Details
| Ticker Symbol | TBPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001583107 |
| CUSIP Number | G8807B106 |
| ISIN Number | KYG8807B1068 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rick E. Winningham M.B.A. | Chief Executive Officer and Director |
| Rhonda F. Farnum | Chief Business Officer and Senior Vice President of Commercial and Medical Affairs |
| Dr. Aine Miller Ph.D. | Senior Vice President of Development and Head of Ireland Office |
| Aziz Sawaf C.F.A. | Senior Vice President of Operations Strategy and Chief Financial Officer |
| Stuart Knight | Senior Vice President of IT&I and Chief Information Officer |
| Brett A. Grimaud Esq. | Senior Vice President, General Counsel and Secretary |
| Stacy L. Pryce | Senior Vice President and Chief Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 25, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 25, 2026 | 8-K | Current Report |
| Aug 21, 2026 | DEFM14A | Filing |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 11, 2026 | PREM14A | Filing |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 10, 2026 | 8-K | Current Report |
| Jun 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 29, 2026 | 8-K | Current Report |